Buy Mots-c 10 mg + bacteriostatic water

€34.70

MOTS-c, 10 mg, with bacteriostatic water, is a synthetic 16-residue peptide format for mitochondrial, analytical and in vitro laboratory research. Pharma Research .eu provides documented European supply subject to lot-specific purity and identity verification.

Category:
Description

Buy MOTS-c, 10 mg + Bacteriostatic Water, for Advanced Laboratory Research in Europe

MOTS-c is a synthetic 16-residue mitochondrial-derived peptide used as a laboratory reagent in peptide analytics, mitochondrial biology and controlled in vitro investigations. The canonical human sequence is MRWQEMGYIFYPRKLR, with reported molecular formula C₁₀₁H₁₅₂N₂₈O₂₂S₂, average molecular mass approximately 2,174.6 Da and CAS Registry Number 1627580-64-6. Pharma Research .eu presents this 10 mg format with bacteriostatic water for qualified European laboratories requiring documented research materials.pubchem.ncbi.nlm.nih+2

Uncompromising Purity and Analytical Characterisation

MOTS-c should be specified as the canonical 16-amino-acid peptide:

H-Met-Arg-Trp-Gln-Glu-Met-Gly-Tyr-Ile-Phe-Tyr-Pro-Arg-Lys-Leu-Arg-OH

The sequence contains two methionine residues, which are relevant to impurity profiling because methionine can undergo oxidation during storage or sample preparation. The N- and C-terminal states should be stated explicitly, as capped or amidated variants may have different molecular masses and analytical behaviour.

For laboratory procurement, the appropriate target is ≥99.0% purity by RP-HPLC, subject to confirmation by the actual batch certificate of analysis. Some research suppliers report ≥99% HPLC purity alongside CoA documentation, but catalogue claims should not replace review of the lot-specific chromatogram.americanpeptides+1

A complete CoA should include:

  • RP-HPLC purity percentage and chromatogram.

  • LC-MS, ESI-MS or high-resolution MS identity confirmation.

  • Exact sequence and terminal-group designation.

  • Molecular mass or principal molecular-ion assignment.

  • Visual appearance of the lyophilised material.

  • Residual-solvent results from synthesis and purification.

  • Water or residual-moisture content, where measured.

  • Counter-ion or salt-form information.

  • Heavy-metal or elemental-impurity results where included in the quality programme.

  • Lot number, manufacture date, retest date and storage requirements.

The commonly reported formula is C₁₀₁H₁₅₂N₂₈O₂₂S₂, with average molecular mass approximately 2,174.6 g/mol and monoisotopic mass near 2,173.11 Da. The material’s reported composition should be reconciled with the CoA because acetate, trifluoroacetate, hydration and residual water can affect the stated product mass.artemispeptides+1

MOTS-c is normally supplied as a white to off-white lyophilised powder. Visual inspection can identify gross discolouration, vial damage or visible contamination, but cannot establish identity or purity. Analytical release should combine appearance assessment with chromatographic purity and mass-spectral confirmation.

High purity is essential for reproducible peptide research because truncated sequences, deletion products, oxidation variants and residual synthesis reagents may affect retention time, ionisation efficiency and assay interpretation. This is especially relevant for a short peptide containing methionine and aromatic residues. Lower-grade or non-characterised material may be unsuitable for quantitative LC-MS work, stability-indicating methods or publication-quality comparisons.

The bacteriostatic water is a separate reagent and should have its own label, expiry information and documentation. Preservatives or excipients may affect cell viability, chromatography, ionisation, adsorption to plastics or other assay characteristics.

Principal Laboratory Applications and Research Methodologies

MOTS-c is suitable for controlled laboratory research involving mitochondrial-derived peptide biology, analytical characterisation and in vitro model systems. All work should be performed by qualified personnel within an appropriately governed university, CRO, pharmaceutical R&D or analytical laboratory.

Peptide identity and impurity profiling. MOTS-c can be used to develop RP-HPLC and LC-MS methods for intact-mass confirmation, retention-time assignment and detection of oxidation or truncation products. A stability-indicating method should distinguish chemical degradation from adsorption, precipitation, sample loss or instrument carryover.

Mitochondrial and metabolic cell models. The peptide may be evaluated in controlled cellular systems examining mitochondrial signalling, stress-response pathways or metabolic read-outs. Such experiments should use validated controls, defined media, solvent blanks and independent confirmation of peptide integrity during the incubation period.

Analytical reference and system-suitability work. A characterised lot may support instrument checks, retention-time monitoring, calibration-curve development and sample-preparation studies. Unless formally certified under an applicable reference-material standard, it should be described as a research reference material or analytical reagent rather than a certified reference material.

Peptide stability studies. Laboratories may investigate the effects of temperature, light, pH, oxidation, container material and freeze–thaw cycles. The two methionine residues make oxidation monitoring particularly relevant. Researchers should consider using mass spectrometry or peptide mapping to confirm whether observed HPLC changes represent oxidation, truncation or another structural modification.

The amount of bacteriostatic water was not specified. Consequently, no final concentration should be printed on the product page. The nominal molar amount of 10 mg MOTS-c is approximately 4.60 µmol using the reported average molecular mass of 2,174.6 g/mol. The final concentration depends on the actual reconstitution volume, purity, salt form, moisture content and validated laboratory method.

Bacteriostatic water should not automatically be assumed suitable for every analytical or cellular workflow. A preservative-containing aqueous medium may require solvent blanks, matrix-effect testing and cell-compatibility assessment. For highly sensitive LC-MS work, laboratories may select a different validated solvent system.

Compound Stability, Optimal Storage, and Safe Handling Protocols

The lyophilised peptide should remain sealed, dry and protected from light until required for a validated procedure. Research references commonly recommend refrigerated or frozen storage for the dry material, with −20°C or −80°C used for longer-term storage depending on the supplier’s stability data. Published handling recommendations vary, so the lot-specific CoA should take precedence.americanpeptides+1

Recommended controls include:

  • Store unopened lyophilised MOTS-c at −20°C unless the CoA specifies another condition.

  • Consider −80°C for extended archival storage where supported by the stability programme.

  • Keep the container tightly closed and protected from moisture and light.

  • Allow a sealed vial to reach room temperature before opening to reduce condensation.

  • Use low-binding tubes where adsorption could affect recovery.

  • Prepare aliquots when repeated access could increase moisture exposure.

  • Store short-term aqueous solutions at 2–8°C only when validated.

  • Use frozen aliquots for longer-term solution storage where supported by data.

  • Avoid repeated freeze–thaw cycles.

  • Record the solvent, concentration, preparation date, operator and storage history.

MOTS-c solutions may be more vulnerable to oxidation, adsorption and physical instability than the sealed dry peptide. Methionine oxidation can produce a measurable mass shift and additional chromatographic species. Light, air exposure, pH and container material should therefore be controlled during method development.

Reconstitution should be carried out using a validated laboratory procedure. Add the aqueous reagent gradually, allow the powder to hydrate and mix gently. Avoid vigorous agitation unless the selected method has demonstrated that it does not increase aggregation or sample loss. Confirm the final concentration analytically where quantitative results are critical.

Handling should follow the current SDS and institutional chemical-risk assessment. Appropriate precautions generally include a certified fume hood or suitable local containment, nitrile gloves, safety goggles and a laboratory coat. Avoid aerosol generation and direct contact with the powder or solution. Dispose of contaminated materials through approved institutional chemical and laboratory-waste procedures.

Technical Specifications and Molecular Attributes

Attribute Specification
Product MOTS-c, 10 mg, supplied with bacteriostatic water
Common designation MOTS-c; mitochondrial-derived peptide
Sequence H-MRWQEMGYIFYPRKLR-OH
Residue count 16 amino acids
IUPAC name Full systematic peptide naming should be confirmed on the CoA; sequence notation is preferred for procurement
CAS Registry Number 1627580-64-6, subject to confirmation against the supplied batch documentation
Molecular formula C₁₀₁H₁₅₂N₂₈O₂₂S₂
Average molecular mass Approximately 2,174.6 g/mol
Monoisotopic mass Approximately 2,173.11 Da
Physical state and colour Lyophilised white to off-white powder
Solubility profile Aqueous reconstitution may be feasible; solvent and buffer compatibility require assay-specific validation
Typical purity Proposed target ≥99.0% by RP-HPLC; verify the lot-specific result
Identity testing LC-MS, ESI-MS or high-resolution MS
Companion reagent Bacteriostatic water; volume and formulation should be confirmed on the pack documentation
Long-term storage Typically −20°C or −80°C, sealed and protected from light and moisture

The canonical sequence, formula, CAS number and molecular mass are reported by public chemistry and peptide-reference sources. Some commercial catalogue records show inconsistent formulas, so the supplier’s sequence and analytical data should be treated as controlling for procurement.pubchem.ncbi.nlm.nih+3

Pharma Research .eu: Your Premier EU Vendor for High-Purity Reagents

Pharma Research .eu can present MOTS-c as a documented European laboratory reagent for analytical chemists, biochemists and laboratory managers requiring a defined mitochondrial-derived peptide. The product file should include a batch-specific CoA, SDS, sequence designation, purity result, identity data, storage instructions and documentation for the bacteriostatic-water component.

Any claim that Pharma Research .eu operates an ISO 9001-certified quality-management system should be supported by a current certificate identifying the issuing body, scope and validity. Claims regarding discreet or temperature-controlled logistics across EU member states should likewise be verified for the destination, carrier route, packaging and applicable transport requirements.

A quality-focused supplier should be able to discuss:

  • Canonical MOTS-c sequence and terminal groups.

  • Methionine-oxidation monitoring.

  • Free-peptide versus acetate or hydrated molecular mass.

  • RP-HPLC purity and LC-MS identity testing.

  • Residual solvents, moisture and elemental-impurity reporting.

  • Packaging configuration and container-closure integrity.

  • Compatibility of bacteriostatic water with analytical workflows.

  • Storage, transport and reconstitution documentation.

Pharma Research .eu should therefore be described as a potential European source for research-grade MOTS-c, with vendor-specific certification and logistics claims verified through current records. The material is intended strictly for controlled laboratory research and analytical use by qualified personnel under applicable institutional procedures.

Reviews (0)

Reviews

There are no reviews yet.

Be the first to review “Buy Mots-c 10 mg + bacteriostatic water”

Your email address will not be published. Required fields are marked *

Shipping & Delivery

MAECENAS IACULIS

Vestibulum curae torquent diam diam commodo parturient penatibus nunc dui adipiscing convallis bulum parturient suspendisse parturient a.Parturient in parturient scelerisque nibh lectus quam a natoque adipiscing a vestibulum hendrerit et pharetra fames nunc natoque dui.

ADIPISCING CONVALLIS BULUM

  • Vestibulum penatibus nunc dui adipiscing convallis bulum parturient suspendisse.
  • Abitur parturient praesent lectus quam a natoque adipiscing a vestibulum hendre.
  • Diam parturient dictumst parturient scelerisque nibh lectus.

Scelerisque adipiscing bibendum sem vestibulum et in a a a purus lectus faucibus lobortis tincidunt purus lectus nisl class eros.Condimentum a et ullamcorper dictumst mus et tristique elementum nam inceptos hac parturient scelerisque vestibulum amet elit ut volutpat.